









Markets
/
Stocks
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

View Detailed Chart

3.720USD

+0.035+0.95%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

973.32MMarket Cap

LossP/E TTM



Akebia Therapeutics Inc

3.720

+0.035+0.95%

Overview Company Financials

Financials

Intraday

30m

Today

+0.95%

5 Days

+4.49%

1 Month

+2.76%

6 Months

+75.47%

Year to Date

+95.79%

1 Year

+197.60%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts

STRONG BUY

Current Rating

7.400

Target Price

98.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Akebia Therapeutics Inc

AKBA

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.085

Neutral

RSI(14)

51.259

Neutral

STOCH(KDJ)(9,3,3)

37.223

Buy

ATR(14)

0.177

High Vlolatility

CCI(14)

-38.206

Neutral

Williams %R

56.140

Sell

TRIX(12,20)

0.052

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.633

Buy

MA10

3.727

Sell

MA20

3.800

Sell

MA50

3.600

Buy

MA100

2.886

Buy

MA200

2.395

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Ticker SymbolAKBA

CompanyAkebia Therapeutics Inc

CEOMr. John P. Butler

Websitehttps://akebia.com/